The requirement of a minimum of 8 years follow-up imaging may have led to a bias toward having more PKD2 patients since some PKD1 patients reached endpoints excluding their participation before 8 years had elapsed such as end-stage kidney disease, cyst aspirations, and tolvaptan therapy. The gene discussed is PKD2; the disease is cyst.